Today, September 18, marks the 19th National ALS Day. The Italian Society of Neurology (ISN) renews its support for the AISLA-promoted initiative. The observance draws the nation’s attention to the needs of people living with amyotrophic lateral sclerosis and their families, fostering dialogue among the scientific community, healthcare professionals, institutions, and patient associations.
The day also represents an important opportunity to take stock of the progress in research, which is changing the way we understand and address the disease. ALS is no longer considered a uniform pathology, but a set of conditions that can exhibit biological, genetic, and clinical differences, paving the way for increasingly personalized approaches.
Overview of ALS
In Italy, an estimated 6,800 people live with ALS, with an incidence of about 3 new cases per 100,000 people per year.
«The ISN’s involvement in National ALS Day promoted by AISLA stems from the belief that research, care, and awareness must advance together—
Mario Zappia, president of the Italian Society of Neurology. – In recent years, research has significantly improved our understanding of the biological mechanisms underlying the disease. Today we know that behind the same diagnosis there can be different forms, and this heterogeneity must be taken into account in the development of new diagnostic and therapeutic tools».
The growing ability to integrate genetic data, biomarkers, neurophysiological methods, advanced neuroimaging techniques, and neuropsychological assessments offers, in fact, an increasingly precise view of the disease and its different clinical profiles.
«Today we are able to read ALS with tools that, until a few years ago, we did not have at our disposal»—
Cristina Moglia, coordinator of the Motor Neuron Diseases Study Group of the ISN. “The integration of genetic data, biological markers, and clinical information allows us to describe the heterogeneity of the disease more accurately and identify subgroups of patients with specific characteristics. It is a crucial step toward a medicine truly based on the biological characteristics of the individual.”
Outlook and Future Challenges
From genetics to biomarkers, from artificial intelligence to new therapies, ALS research is opening unprecedented prospects in understanding and managing the disease. In this landscape, Italian research plays a leading role across the entire path of innovation, while neurorehabilitation and assistive technologies are increasingly contributing to improving autonomy and quality of life for people with ALS.
«The challenge for the coming years will be to more effectively integrate therapeutic innovation, biological research, neurorehabilitation, and new technologies within personalized care pathways—
concludes Moglia. “ALS remains a complex disease, but today we have tools and knowledge that allow us to look to the future with perspectives that are new compared with the past».
Subscribe to Karla Miller
